Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sucampo Pharmaceuticals, Inc. : Sucampo Receives $10 Million Milestone Payment from Takeda on First Sale of AMITIZA® (lubiprostone) for OIC in the US

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2013 | 02:05am CEST

AMITIZA is the World's First and Only Oral Medication Approved for Treatment of Opioid-Induced Constipation in Adults with Chronic, Non-cancer Pain

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that it has received a $10 million milestone payment from Takeda Pharmaceutical Company Limited (Takeda), pursuant to the existing collaboration and license agreement between SPI and Takeda. The milestone payment was triggered by the commercial launch of AMITIZA® (lubiprostone) (24 mcg daily) in the United States for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. The effectiveness of AMITIZA in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established.

This is the third indication for AMITIZA, which is also approved in the U.S. for the treatment of chronic idiopathic constipation (CIC) in adults (24 mcg twice daily) and irritable bowel syndrome with constipation (IBS-C) in adult women (8 mcg twice daily). There are more than 200 million prescriptions for opioid use in the U.S. annually, and a substantial number of these prescriptions are for non-cancer chronic pain. Scientific literature indicates that approximately 40-80% of patients taking opioids chronically for non-cancer pain report constipation. Some patients may discontinue opioid therapy and thereby endure pain, rather than suffer from the constipation the opioids cause.

"Millions of patients in the US have been suffering from OIC, and until the approval of AMITIZA for OIC, which received priority review status from the FDA, there were no oral prescription products available to treat it," said Sucampo's Chairman, Chief Executive Officer, and Chief Scientific Officer Ryuji Ueno, M.D., Ph.D., Ph.D. "Opioids decrease secretion of intestinal fluid, one of the key factors in causing OIC. As a locally acting ClC-2 channel activator, AMITIZA restores fluid secretion and can lead to relief for those suffering from OIC. We are pleased that with this third indication for AMITIZA, we can further our mission of meeting the unmet medical needs of patients."

AMITIZA is a specific activator of ClC-2 chloride channels in the intestinal epithelium, and it bypasses the antisecretory action of opiates. AMITIZA is the world's first chloride channel activator approved for therapeutic use. With more than seven million prescriptions dispensed worldwide since 2006, it is the first and currently the only oral prescription medicine in the world approved for OIC in adults with chronic, non-cancer pain.

In 2004, SPI and Takeda entered into a collaboration and license agreement for AMITIZA for the United States and Canada.

About Opioid Induced Constipation (OIC)

OIC is a common adverse effect of chronic opioid use. Binding of opioids to peripheral opioid receptors in the gastrointestinal tract decreases both muscle motility and secretion of electrolytes, such as chloride, and causes subsequent reduction in small intestinal fluid. Together, these processes result in OIC, which is characterized by infrequent and incomplete evacuation of stool, hard stool consistency, and straining associated with bowel movements.

About AMITIZA

AMITIZA (lubiprostone) capsules are indicated for the treatment of chronic idiopathic constipation (CIC) in adults and opioid-induced constipation (OIC) in adults with chronic, non-cancer pain (24 mcg twice daily). The effectiveness in patients with OIC taking diphenylheptane opioids (e.g., methadone) has not been established. AMITIZA is also indicated for irritable bowel syndrome with constipation (IBS-C) in women > 18 years old (8 mcg twice daily).

Important Safety Information

  • AMITIZA (lubiprostone) is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider (HCP) to confirm the absence of such an obstruction prior to initiating AMITIZA treatment.
  • Patients taking AMITIZA may experience nausea. If this occurs, concomitant administration of food with AMITIZA may reduce symptoms of nausea. Patients who experience severe nausea should inform their HCP.
  • AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. Patients should be instructed to discontinue AMITIZA and inform their HCP if severe diarrhea occurs.
  • Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their HCP. Some patients have discontinued therapy because of dyspnea.
  • In clinical trials of AMITIZA (24 mcg twice daily vs placebo; N=1113 vs N=316, respectively) in patients with CIC, the most common adverse reactions (incidence > 4%) were nausea (29% vs 3%), diarrhea (12% vs <1%), headache (11% vs 5%), abdominal pain (8% vs 3%), abdominal distension (6% vs 2%), and flatulence (6% vs 2%).
  • In clinical trials of AMITIZA (24 mcg twice daily vs. placebo; N=860 vs. N=632) in patients with OIC, the most common adverse reactions (incidence >4%) were nausea (11% vs 5%) and diarrhea (8% vs 2%).
  • In clinical trials of AMITIZA (8 mcg twice daily vs. placebo; N=1011 vs. N=435, respectively) in patients with IBS-C the most common adverse reactions (incidence > 4%) were nausea (8% vs 4%), diarrhea (7% vs 4%), and abdominal pain (5% vs 5%).
  • Concomitant use of diphenylheptane opioids (e.g., methadone) may interfere with the efficacy of AMITIZA.
  • The safety of AMITIZA in pregnancy has not been evaluated in humans. Based on animal data, AMITIZA may cause fetal harm. AMITIZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when AMITIZA is administered to a nursing woman. Advise nursing women to monitor infants for diarrhea.
  • Reduce the dosage in CIC and OIC patients with moderate and severe hepatic impairment. Reduce the dosage in IBS-C patients with severe hepatic impairment.

For further information, please visit www.sucampo.com/products for complete Prescribing Information.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com.

AMITIZA® is a registered trademark of Sucampo AG.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by reference.

Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
staylor@sucampo.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SUCAMPO PHARMACEUTICALS, I
08/11 SUCAMPO PHARMACEUTICALS : Study Results Published in The Lancet Demonstrate Safe..
08/07 SUCAMPO PHARMACEUTICALS : Drug Makers Stock Performance Review -- DURECT, Sucamp..
08/02 SUCAMPO PHARMACEUTICALS : reports 2Q loss
08/02 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
08/02 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
08/02 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Results of Operations ..
08/02 Sucampo Reports Second Quarter 2017 Financial Results
08/02 SUCAMPO PHARMACEUTICALS, INC. : Investor Network: Sucampo Pharmaceuticals, Inc. ..
07/19 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Departure of Directors..
07/19 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regul..
More news
News from SeekingAlpha
08/02 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q2 2017 Results - Earn..
08/02 Sucampo Pharma Q2 revenues up 15%; non-GAAP EPS up 17%; reiterates guidance
08/02 Sucampo beats by $0.01, beats on revenue
07/27 SUCAMPO : A Shift Toward Rare Diseases
05/23 Sucampo Pharmaceuticals (SCMP) Presents At Bank of America Merrill Lynch 2017..
Financials ($)
Sales 2017 235 M
EBIT 2017 99,4 M
Net income 2017 -91,5 M
Debt 2017 243 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 11,02
EV / Sales 2017 3,07x
EV / Sales 2018 2,49x
Capitalization 477 M
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Technical analysis trends SUCAMPO PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 18,7 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Matthew Maxwell Donley EVP-Human Resources & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICALS, INC.-25.83%477
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
GILEAD SCIENCES0.70%94 170
REGENERON PHARMACEUTICALS26.41%50 145
VERTEX PHARMACEUTICALS101.07%37 346